strong guidanc lower ebit
outlook reduc segment
balanc beat vs lower guid given market tumult
amerisourcebergen pretti solid across board segment beat
revenu ebit lead bottom-lin out-performance also take
number import step help respond outbreak despit
strength compani reduc ep guidanc rang midpoint
ebit growth pharma segment widen ebit growth
segment mwi world courier abc lower meaning clearli color
move piec key stock perform driven manag
seen recent basi rel demand slowdown much conservat
built due volatil current seen across healthcar util maintain
under-perform rate see lack increment upsid driver custom
exposur await detail call
pharma ebit/ep expect
adjust ep street ep ep
revenu street estim estim
pharmaceut revenu street estim
estim pharma ebit came vs street
estim ebit came vs
consensu estim estim varianc analysi
ep guidanc lower
lower ep guidanc vs
estim consensu median estim within annual guidanc
revenu growth lower mid-to-high singl digit low-to-mid singl digit
growth adjust oper expens expect increas low-singl
digit rang versu mid-singl digit growth previous adjust oper incom
growth widen mid-singl digit growth low-to-mid-singl digit growth
pharmaceut distribut segment oper incom lowered/widen mid-
singl digit growth low-to-mid singl digit growth oper incom growth
lower high-singl digit growth low-singl digit declin weight averag
share expect previous
topic call
import topic commentari around current script growth trend
fluctuat script sale throughout april given volatil seen across variou
channel outbreak factor guidanc chang also
look trajectori brand gener inflat given
sever month data calendar also expect manag address
on-going convers manufactur regard shift price dynam
includ price shift occur result demand volatil
throughout press report explor acquir eu
wholesal busi commentari capit deploy prioriti focu
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
evalu purchas
wait color
million except per share data
revenu
compani file bofa secur global research
note adjust ebit exclud opioid-rel litig expens
price object base ep multipl
five-year averag five-year high although would argu
artifici high due period gener inflat also repres bigger
discount vs last five year think discount warrant given
incorpor modest growth slowdown seen rest suppli
chain well encompass competit risk
upsid risk po potenti volum pickup increas buyside/sellsid
spread opportun cost save deepen relationship
walgreen largest custom downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market on-going
uncertainti headlin relat opioid litig process lack avail
attract capit deploy opportun market volatil tie
outbreak potenti govern intervent drug price control
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
